Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Beam Therapeutics (BEAM) Income from Continuing Operations (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Income from Continuing Operations for 7 consecutive years, with 6805000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 92.47% to 6805000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 331246000.0, a 10.56% increase, with the full-year FY2025 number at 79992000.0, up 78.77% from a year prior.
  • Income from Continuing Operations was 6805000.0 for Q4 2025 at Beam Therapeutics, up from 112728000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 143522000.0 in Q4 2023 to a low of 200394000.0 in Q1 2021.
  • A 5-year average of 74940750.0 and a median of 86516000.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: plummeted 621.93% in 2021, then soared 274.21% in 2023.
  • Beam Therapeutics' Income from Continuing Operations stood at 63430000.0 in 2021, then decreased by 29.88% to 82384000.0 in 2022, then skyrocketed by 274.21% to 143522000.0 in 2023, then tumbled by 162.95% to 90354000.0 in 2024, then skyrocketed by 92.47% to 6805000.0 in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Income from Continuing Operations are 6805000.0 (Q4 2025), 112728000.0 (Q3 2025), and 102291000.0 (Q2 2025).